2023
Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma
Quyn A, Murthy S, Gould L, Said H, Tiernan J, Sagar P, Antoniou A, Jenkins I, Burns E. Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma. Colorectal Disease 2023, 25: 2131-2138. PMID: 37753947, DOI: 10.1111/codi.16736.Peer-Reviewed Original ResearchConceptsAnal squamous cell carcinomaSquamous cell carcinomaDisease-free survivalR0 resectionR1/R2 resectionPelvic exenterationOverall survivalRecurrent diseaseCell carcinomaTreated with pelvic exenterationComplete R0 resectionPelvic exenteration surgeryAnal cancer incidenceR0 resection rateMedian Follow-UpPoorer overall survivalR1/2 resectionR1 resectionR2 resectionExenteration surgeryOncological outcomesResection ratePrimary endpointRetrospective reviewTreatment modalities
2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapy
2020
Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma
Catenacci D, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala M, Narula S, Alpert L, Setia N, Xiao S, Hart J, Siddiqui U, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron S, Liao C, Polite B, Kindler H, Turaga K, Prachand V, Roggin K, Ferguson M, Posner M. Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open 2020, 3: e1921290. PMID: 32058557, DOI: 10.1001/jamanetworkopen.2019.21290.Peer-Reviewed Original ResearchConceptsLocally advanced gastroesophageal adenocarcinomaPathological response gradeAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaResection rateMargin-negativeResponse gradeMargin-negative resection rateMedian disease-free survivalUGT1A1 genotype groupsMedian overall survivalLocally advanced adenocarcinomaHigher adverse eventsR0 resection rateDisease-free survivalCoprimary end pointsPhase 2 trialRate of recurrenceIntestinal-type tumorsR0 resectionR1 resectionAdvanced adenocarcinomaNeoadjuvant chemotherapyPerioperative therapyOverall survival
2019
Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).
Catenacci D, Chase L, Lomnicki S, Karrison T, Marsh R, Rampurwala M, Narula S, Alpert L, Setia N, Xiao S, Hart J, Siddiqui U, Liao C, Polite B, Kindler H, Turaga K, Prachand V, Roggin K, Ferguson M, Posner M. Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA). Journal Of Clinical Oncology 2019, 37: 4050-4050. DOI: 10.1200/jco.2019.37.15_suppl.4050.Peer-Reviewed Original ResearchPathological response gradeG3+ toxicityGastroesophageal adenocarcinomaUGT1A1 genotypeGastric bodyGastroesophageal adenocarcinoma patientsIntestinal type histologyR0 resectionR1 resectionComplete resectionHER2 statusDose reductionHistological subtypesPET responsePostoperative dataMedian ageTumor siteSurvival outcomesBiweekly cyclesResponse gradeResectionEfficacyUGT1A1DoseEndpoint
2016
The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas
Stahl JM, Corso CD, Park HS, An Y, Rutter CE, Han D, Roberts KB. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. European Journal Of Surgical Oncology 2016, 43: 168-174. PMID: 27335080, DOI: 10.1016/j.ejso.2016.05.031.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasOverall survivalR1 resectionR0 resectionMargin statusNational Cancer Data BaseRetroperitoneal soft tissue sarcomaCox proportional hazards regressionPropensity scoreMultivariable logistic regression modelMedian overall survivalMicroscopic margin statusPre-operative RTReceipt of RTUnderwent R0 resectionSuperior overall survivalSmaller tumor sizeLow tumor gradeProportional hazards regressionLog-rank testRetroperitoneal soft tissueLogistic regression modelsLiposarcoma histologyR1 patientsRadiotherapy receiptLong‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features
Abdelfatah E, Guzzetta AA, Nagarajan N, Wolfgang CL, Pawlik TM, Choti MA, Schulick R, Montgomery EA, Meyer C, Thornton K, Herman J, Terezakis S, Frassica D, Ahuja N. Long‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features. Journal Of Surgical Oncology 2016, 114: 56-64. PMID: 27076350, PMCID: PMC4917421, DOI: 10.1002/jso.24256.Peer-Reviewed Original ResearchConceptsCompartmental resectionRPS patientsSurgical resectionPrognostic factorsR0/R1 marginsR0/R1 resectionEn bloc surgical resectionBloc surgical resectionCornerstone of therapyMainstay of treatmentFive-year survivalRetrospective chart reviewPresence of metastasesEn bloc resectionExtent of resectionConnective tissue tumorsJohns Hopkins HospitalWarrants further investigationR1 resectionRetroperitoneal sarcomaChart reviewMedian survivalR1 marginsDistal recurrenceLocal recurrence
2015
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer 2015, 121: 4141-4149. PMID: 26280559, DOI: 10.1002/cncr.29652.Peer-Reviewed Original ResearchConceptsImproved overall survivalNational Cancer Data BaseOverall survivalPancreatic adenocarcinomaAdjuvant chemotherapyR0 resectionR1 resectionPN1 diseaseNational cohortSubset analysisPropensity scoreAddition of radiotherapyMedian radiotherapy doseOutcome of chemotherapyLarge national cohortPT1-3N0CRT groupClinicopathologic characteristicsCRT patientsRandomized comparisonCox regressionRadiotherapy doseOptimal treatmentPancreatic cancerUnivariate analysis
2014
Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survival
2012
Neoadjuvant chemoradiation and intraoperative electron irradiation for locally unresectable/borderline resectable pancreas adenocarcinoma.
Ashman J, Moss A, Callister M, Reddy K, Mulligan D, Gunderson L, Borad M. Neoadjuvant chemoradiation and intraoperative electron irradiation for locally unresectable/borderline resectable pancreas adenocarcinoma. Journal Of Clinical Oncology 2012, 30: 327-327. DOI: 10.1200/jco.2012.30.4_suppl.327.Peer-Reviewed Original ResearchIntraoperative electron irradiationOverall survivalNeoadjuvant chemotherapyNeoadjuvant therapyPancreas adenocarcinomaPancreatic cancerKaplan-Meier survival analysisThree-year OSAdvanced pancreatic cancerMedian overall survivalNovel systemic agentsLog-rank testCurative surgeryR1 patientsR1 resectionDistant diseaseLocal progressionNeoadjuvant chemoradiationPreoperative therapyMedian survivalResection statusSurgical resectionSystemic agentsComplete resectionLocal therapy
2011
Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical marginsPresence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Indian Journal Of Surgical Oncology 2011, 2: 9-15. PMID: 22696140, PMCID: PMC3373004, DOI: 10.1007/s13193-011-0073-7.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPresence of PanINPancreatic intraepithelial neoplasiaResection marginsPanIN lesionsTransection marginR0 resectionIntraepithelial neoplasiaPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsOverall median survivalPancreatic resection marginPancreatic transection marginIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsMargin status
2009
Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series
Reddy S, Cameron JL, Scudiere J, Hruban RH, Fishman EK, Ahuja N, Pawlik TM, Edil BH, Schulick RD, Wolfgang CL. Surgical Management of Solid-Pseudopapillary Neoplasms of the Pancreas (Franz or Hamoudi Tumors): A Large Single-Institutional Series. Journal Of The American College Of Surgeons 2009, 208: 950-957. PMID: 19476869, PMCID: PMC3109868, DOI: 10.1016/j.jamcollsurg.2009.01.044.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary neoplasmMalignant potentialFormal surgical resectionMedian tumor sizeOutcomes of patientsLymph node metastasisRare pancreatic tumorR1 resectionAbdominal painR0 resectionR2 resectionInstitutional seriesMost patientsSurgical resectionUnrelated causesClinicopathologic characteristicsComplete resectionMedian ageNode metastasisDistant metastasisPerineural invasionSurgical managementCommon symptomsLongterm outcomesTumor size
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply